COVID-19 May Briefing: The UK&I Healthcare Ecosystem FightbackThe third webinar* in the COVID-19 monthly briefing series is designed to provide insight from life sciences thought-leaders Share XCOVID-19 May Briefing: The UK&I Healthcare Ecosystem Fightbackhttps://pharmaphorum.com/r-d/covid-19-may-briefing-the-uki-healthcare-ecosystem-fightback/
Unlocking health data to improve oncology outcomesThe NHS’ globally unique health data ecosystem has the potential to improve health outcomes. With around 363,000 new Share XUnlocking health data to improve oncology outcomeshttps://pharmaphorum.com/oncology/unlocking-health-data-to-improve-oncology-outcomes/
The new global digital health paradigm in life sciencesDigital transformation has long been a priority for all life science companies and it has been made even Share XThe new global digital health paradigm in life scienceshttps://pharmaphorum.com/r-d/10-years-in-10-days-the-new-global-digital-health-paradigm-in-life-sciences/
COVID-19 briefing: coronavirus impacts for UK and Ireland pharma and biotechOverview This April webinar is part of IQVIA’s monthly updates on the impact of COVID-19 and its implications Share XCOVID-19 briefing: coronavirus impacts for UK and Ireland pharma and biotechhttps://pharmaphorum.com/r-d/iqvia-covid-19-april-briefing-impact-for-pharma-and-biotech/
Vaccines trials in the COVID-19 era and tech’s role in speeding studiesOverview The COVID-19 outbreak has exposed the challenges pharmaceutical companies face as they race to develop a coronavirus Share XVaccines trials in the COVID-19 era and tech’s role in speeding studieshttps://pharmaphorum.com/r-d/vaccines-trials-covid-19-coronavirus/
The COVID-19 coronavirus and pharma and biotech continuity planningOverview Pharmaceutical and biotech companies around the globe are working with Governments to address the COVID-19 outbreak, from Share XThe COVID-19 coronavirus and pharma and biotech continuity planninghttps://pharmaphorum.com/r-d/the-potential-impact-of-coronavirus-covid-19-for-global-pharma-and-biotech-continuity/
How ‘thinking modular’ might ease digital content overload in pharmaOverview In today’s digital world it is increasingly hard for pharmaceutical companies to successfully differentiate new brands based Share XHow ‘thinking modular’ might ease digital content overload in pharmahttps://pharmaphorum.com/sales-marketing/how-thinking-modular-might-ease-digital-content-overload-in-pharma/
Applying behavioural interventions in chronic diseasesOverview Chronic diseases are the leading cause of death and disability worldwide and have a staggering impact on Share XApplying behavioural interventions in chronic diseaseshttps://pharmaphorum.com/sales-marketing/applying-behavioural-interventions-in-chronic-diseases/
Informed patients: evolving healthcare, clinical trials and medical informationOverview Patients are more informed than ever about their conditions and what is available for them to improve Share XInformed patients: evolving healthcare, clinical trials and medical informationhttps://pharmaphorum.com/sales-marketing/informed-patients-evolving-healthcare-clinical-trials-and-medical-information/
